A complex interplay of environmental factors impacts the metabolism of human cells, but neither traditional culture media nor mouse plasma mimic the metabolite composition of human plasma. Here, we developed a culture medium with polar metabolite concentrations comparable to those of human plasma (human plasma-like medium [HPLM]). Culture in HPLM, relative to that in traditional media, had widespread effects on cellular metabolism, including on the metabolome, redox state, and glucose utilization. Among the most prominent was an inhibition of de novo pyrimidine synthesis-an effect traced to uric acid, which is 10-fold higher in the blood of humans than of mice and other non-primates. We find that uric acid directly inhibits uridine monophosphate synthase (UMPS) and consequently reduces the sensitivity of cancer cells to the chemotherapeutic agent 5-fluorouracil. Thus, media that better recapitulates the composition of human plasma reveals unforeseen metabolic wiring and regulation, suggesting that HPLM should be of broad utility.
INTRODUCTION
There is a resurgence of interest in the metabolism of mammalian cells and in understanding the metabolic adaptations that enable cells to grow and proliferate (DeBerardinis et al., 2008; Hosios et al., 2016; Keibler et al., 2016; Lunt and Vander Heiden, 2011; MacIver et al., 2013; Pearce et al., 2013; Vander Heiden et al., 2009) . Cells in culture are commonly used to study metabolism (DeBerardinis and Chandel, 2016) , and despite the appreciation that metabolic networks are flexible (Boroughs and DeBerardinis, 2015; Cairns et al., 2011; Cantor and Sabatini, 2012; Lehué dé et al., 2016; Olson et al., 2016) and greatly influenced by environmental metabolites (Davidson et al., 2016; DeBerardinis and Chandel, 2016; DeNicola and Cantley, 2015; Hensley et al., 2016; Maddocks et al., 2013; Mayers et al., 2016; Yuneva et al., 2012) , there has been relatively little investigation of how the small molecule composition of culture media impacts metabolism.
Traditional synthetic cell culture media were not developed with the primary desire of mimicking human plasma, but, rather, to address the need for large amounts of medium with less inherent variability than natural media such as biological fluids and tissue extracts (Freshney, 2010) . Upon defining the minimum nutritional requirements of two cell types (Eagle, 1955a (Eagle, , 1955b , Eagle formulated one of the first standardized synthetic media, Basal Medium Eagle (BME), over half a century ago (Eagle, 1955c) . Soon after, Eagle developed Minimal Essential Medium (MEM) (Eagle, 1959) , and within the ensuing decade, Dulbecco and Freeman formulated DMEM originally for the culture of mouse embryonic cells (Dulbecco and Freeman, 1959) , and Moore et al. (1967) developed RPMI 1640 for that of blood cells. Even though the nutrient concentrations of DMEM and RPMI 1640 poorly resemble those of human plasma, most studies of metabolism examine cells cultured in these media.
Efforts have been made to adjust the concentrations of media components, usually one or several nutrients at a time, to better reflect physiologic conditions (Birsoy et al., 2014; Favaro et al., 2012; Kamphorst et al., 2015; Pan et al., 2016; Schug et al., 2015; Tardito et al., 2015; Yao et al., 2016) . Most such modified media not only contain other nutrients at non-physiological levels, but also lack defined concentrations of many metabolites now known to be present in human plasma. In mice and humans, great progress has been made in the study of metabolism in vivo, usually by monitoring the utilization patterns of isotope-labeled nutrients in tumors or normal tissues (Comerford et al., 2014; Commisso et al., 2013; Davidson et al., 2016; Hensley et al., 2016; Mashimo et al., 2014; Mayers et al., 2016; Sellers et al., 2015; Venneti et al., 2015; Yuneva et al., 2012) . While such models provide a physiologically relevant environmental context for the study of metabolism, they do not permit the scope and flexibility of experimentation possible in cultured cells. In addition, there are multiple examples of differences in the metabolism of mice and humans (Adelman et al., 1988; Chandrasekera and Pippin, 2014; Demetrius, 2005; Elsea and Lucas, 2002; Martignoni et al., 2006) , and it is unclear how well the metabolite composition of murine plasma reflects that of humans.
Here, we developed a medium with a defined set of metabolites and salts at the concentrations reported for adult human plasma (human plasma-like medium [HPLM] ). Culture in HPLM dramatically alters the metabolism of cells compared to that in traditional media. Among its most prominent effects is an inhibition of de novo pyrimidine synthesis, which we traced to uric acid-a metabolite whose plasma concentration is up to an order of magnitude greater in higher primates than in other mammals (Á lvarez-Lario and Macarró n-Vicente, 2010; Kratzer et al., 2014; Wu et al., 1992) . We find that uric acid directly inhibits uridine monophosphate synthase (UMPS) and consequently, reduces the sensitivity of cancer cells to the chemotherapeutic agent 5-fluorouracil. While we traced the effects of HPLM on pyrimidine metabolism to uric acid, the causes for most of the metabolic effects we observe are unknown and of potential interest for future study.
RESULTS AND DISCUSSION

A Cell Culture Medium that Reflects the Polar Metabolite Composition of Human Plasma
The classic synthetic cell culture media, BME, MEM, DMEM, and RPMI 1640, contain glucose, amino acids, vitamins, and salts at concentrations that in large part do not reflect those of human plasma ( Figure 1A ; Table S1 ). These media also lack additional components revealed to be present by mass spectrometric and NMR analyses of plasma (Psychogios et al., 2011) . Instead, basal media are often supplemented with heat inactivated fetal bovine serum (IFS), which contributes an undefined and often unaccounted for cocktail of metabolites, as well as the growth factors and hormones needed for cell proliferation (Freshney, 2010) . Thus, while the impact of environmental factors on cell metabolism is well appreciated (Davidson et al., 2016; DeNicola and Cantley, 2015; Hensley et al., 2016; Maddocks et al., 2013; Mayers et al., 2016; Yuneva et al., 2012) , the interrogation of cultured cells in media that better reflect the metabolite composition of human plasma is largely unexplored ( Figure 1B) .
To begin to address this, we developed a culture medium with a defined collection of metabolites and salt ions at concentrations reported for plasma from healthy adult humans (HPLM) (Psychogios et al., 2011; Wishart et al., 2013) . Although some serum-free media have entirely defined recipes, they often require meticulous tailoring of growth factors to support the culture of different cell types (Freshney, 2010) . Thus, given our hope that HPLM will be of broad utility, we supplemented it with 10% dialyzed IFS (HPLM +dIFS ) to add the growth factors and hormones required for the proliferation of a broad range of cells, while minimizing the addition of polar metabolites at unknown concentrations. We did not attempt to recapitulate the lipophilic components of human serum because the removal of serum lipids present at otherwise unknown concentrations requires a charcoal stripping step that can deplete certain hormones and growth factors. As anticipated, dialyzed IFS contains total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol at concentrations equivalent to those in IFS (Table S1 ). The STAR Methods describes HPLM +dIFS in detail, but, in brief, it contains glucose, proteinogenic amino acids, salts, 27 additional polar metabolites, 10% dialyzed IFS, and vitamins at the same concentrations as RPMI 1640 ( Figure 1C ; Table S1); uses a bicarbonate buffering system at physiological pH, and has an osmolality of $295 mOsm/kg. Because RPMI 1640 (herein RPMI) is the medium of choice for culturing normal blood cells as well as the hematological cancer cells we examine in detail below (Freshney, 2010; Moore et al., 1967) , we chose it as the reference medium for comparing the effects of HPLM +dIFS on cells. We generated two RPMI formulations, each with physiological glucose (5 mM), but supplemented with either 10% IFS (RPMI +IFS ) or 10% dialyzed IFS (RPMI +dIFS ). Metabolite profiling confirmed that the dialysis of IFS substantially reduced its levels of polar metabolites, but had little effect on its lipid contents ( Figure 1D ; Table S1 ). Moreover, it also revealed that fetal bovine serum poorly reflects the metabolic composition of adult human plasma, as the addition of 10% IFS to RPMI did not yield concentrations for many metabolites at 10% of the reported values in human plasma. Similarly, while the concentrations of glucose and many amino acids in mouse plasma in large part resemble those in human plasma, those of other metabolites were very different, including examples that were at least 3-to 10-fold lower (e.g., carnitine and uric acid) or greater (e.g., 3-hydroxybutyrate and taurine) in mouse plasma ( Figure 1D ; Table S1 ). Thus, while murine tumor models are useful for studying metabolism in the context of stromal and immune cells, HPLM +dIFS more closely reflects the polar metabolite composition of human plasma than does mouse plasma. HPLM +dIFS provides the metabolites needed for cancer cell proliferation, as six cell lines representing various human hematological cancers as well as four cell lines from diverse human epithelial cancers proliferated in HPLM +dIFS at rates that were comparable, albeit generally lower, to those in RPMI +IFS and RPMI +dIFS (Figures 1E and S1A) . HPLM +dIFS also supports efficient viral-based transduction ( Figure S1B ), and cells cultured in HPLM +dIFS activated mTORC1 signaling to an extent comparable to those in RPMI +IFS , as detected by phosphorylated S6K1
( Figure S1C ).
Culture of Cells in HPLM Extensively Alters Their Metabolic Landscape and Fate of Glucose Carbons
To test the hypothesis that culturing cells in a medium that better mimics the metabolic composition of human plasma alters cellular metabolism compared to that in established media, we began by comparing the metabolite profiles of cells cultured in HPLM +dIFS to those in RPMI +IFS or RPMI +dIFS . Indeed, HPLM +dIFS profoundly affected the intracellular abundances of many metabolites across multiple pathways, including amino acid, lipid, and nucleotide metabolism ( Figure 2A ; Table S2 ). For several metabolites, such as arginine, asparagine, and taurine, the differences reflected those in the media themselves, while for others, such as aspartate and lactate, they did not.
Most HPLM
+dIFS -induced changes were shared by all six of the cell lines examined, but some were cell line-specific, underscoring how the heterogeneity of cancer (Cantor and Sabatini, 2012; Eason and Sadanandam, 2016; Hu et al., 2013; Shaul et al., 2016) can influence the cellular responses to environmental con- (A) Heatmap of relative concentrations of the indicated components of BME, MEM, DMEM, and RPMI 1640 compared to those in adult human plasma (log 2 -transformed fold changes). Components not present in a medium are marked as absent. See Table S1 for further detail regarding this heatmap and the concentrations of all metabolites. (B) Schematic depicting the different metabolic milieus to which cells in culture and in vivo are exposed. (C) Components of human plasma-like medium (HPLM). The concentrations of the components depicted by red-colored boxes reflect those in adult human plasma. See Table S1 for the detailed formulation of HPLM. (D) Heatmap of relative concentrations of the indicated components in denoted media and mouse plasma compared to those in human plasma (log 2 -transformed fold changes). N/D, fold change value could not be determined. See Table S1 for detailed criteria used to generate this heatmap and for the concentrations of all metabolites. RPMI +IFS : RPMI 1640 with 5 mM glucose and 10% IFS. RPMI +dIFS : RPMI 1640 with 5 mM glucose and 10% dialyzed IFS. HPLM +dIFS : HPLM containing 10% dialyzed IFS. *The following metabolites were not readily detected in media samples by the metabolite profiling method used: acetate, acetone, cysteine, formate, galactose, glutathione, and malonate. (E) Relative growth rates of six hematological cancer cell lines cultured in HPLM +dIFS compared to in RPMI +IFS (blue) or in RPMI +dIFS (gray) (mean ± SD, n = 3; *p < 0.05) (left). Specific growth rates (m) were calculated using natural log-transformed growth curves (right). Cell lines represent the following hematological cancers: K562 (chronic myeloid leukemia), KMS12BM (multiple myeloma), NOMO1 (acute myeloid leukemia), P12-Ichikawa (T cell acute lymphoblastic leukemia), SEM (B cell acute lymphoblastic leukemia), SUDHL4 (B cell lymphoma). See also Figure S1 and Table S1 . (mean ± SD, n = 3). (C) Intracellular GSH/GSSG ratios following culture in HPLM +dIFS compared to that in RPMI +IFS (blue) or to RPMI +dIFS (gray) (mean ± SD, n = 3, *p < 0.05).
(D) Intracellular NAD/NADH ratios following culture in HPLM +dIFS compared to that in RPMI +IFS (blue) or to RPMI +dIFS (gray) (mean ± SEM, n = 3, *p < 0.05).
See also Figure S2 and Table S2. in oxoglutarate only in KMS12BM cells. Culture in HPLM +dIFS also induced widespread and largely similar alterations to the metabolomes of several other cell types, including a variety of epithelial cancer cell lines (786-0, A549, MCF7, and SW620), an early passage undifferentiated sarcoma cell line (CLF-PED-015T) (Hong et al., 2016) , a normal foreskin fibroblast cell line (BJ), and a primary acute myeloid leukemia sample ( Figure S2A ; Table S3 ). Culture in HPLM +dIFS did not affect the energy charge (Atkinson, 1968) in any cell line ( Figure 2B ) but did have cell line-specific effects on the redox state as reflected by changes to the ratios of two redox couples: GSH/GSSG ( Figure 2C ) and NAD/ NADH ( Figure 2D ). HPLM +dIFS did not markedly alter the correlation between rates of glucose consumption and lactate secretion across four cell lines examined ( Figure S2B ), suggesting that it had little effect on the aerobic glycolysis phenotype common to most cancer cells (Hosios et al., 2016; Jain et al., 2012) . In contrast, HPLM +dIFS reduced basal oxygen consumption rates in two of the same four cell lines, revealing a cell line-specific impact on mitochondrial respiration ( Figure S2C ). Lastly, the levels of defined components in HPLM +dIFS and RPMI +IFS were largely unaffected following the culture of three cell lines in conditions identical to those used to obtain whole-cell metabolite profiles ( Figure S2D ; Table S3 ).
To specifically study glucose utilization, we compared the 13 C-labeling patterns for several metabolites following the culture of three cell lines (K562, NOMO1, and P12-Ichikawa) in HPLM +dIFS containing [U-13 C]-glucose to those in RPMI +IFS or RPMI +dIFS ( Figure 3A ; Table S2 ). Interestingly, while HPLM +dIFS contains pyruvate at a concentration of $40 mM, which is over 10-fold greater than that of RPMI +IFS , it did not affect the fraction of pyruvate labeled with three 13 C (M3) ( Figure 3B ). However, HPLM +dIFS did affect the metabolism of glucose-derived Acetyl-CoA generated by the oxidation of pyruvate, as reflected by reductions in the M2 labeling of citrate in the TCA cycle and of certain acetylated amino acids ( Figure 3C ; Table S2 ). HPLM +dIFS also decreased the fraction of M3-glycerophosphocholine, suggesting that it may induce alterations in glucose utilization for lipid synthesis ( Figure 3D ). As with the metabolome, HPLM +dIFS also had cell-line-dependent effects on glucose utilization. Among the most prominent was a dramatic reduction in the M6 labeling of F6P/G1P only in K562 and P12-Ichikawa cells ( Figure 3E ), suggesting that sources beyond exogenous glucose contribute to F6P/G1P pools when these cells are cultured in HPLM +dIFS . Additionally, while HPLM +dIFS contains alanine at $620 mM, a concentration nearly 5-fold greater than that of RPMI +IFS , it did not affect the fraction of M3-alanine in two cell lines. However, it reduced by over 2-fold the M3 labeling of alanine in P12-Ichikawa cells (Figure 3F Figure 3H ). Similarly, though HPLM +dIFS contains asparagine at a concentration of 50 mM, which is nearly 7-fold less than that of RPMI, it dramatically increased the fraction of M1-asparagine, but only in K562 and NOMO1 cells ( Figure 3I ). In addition, despite containing valine at a concentration roughly equivalent to that of RPMI, HPLM +dIFS nonetheless increased the fraction of M1-valine, but only in K562 and P12-Ichikawa cells ( Figure 3J) Table S2 ).
Collectively, these data reveal that while aerobic glycolysis was essentially unaffected, culture in HPLM +dIFS , compared to that in RPMI, had widespread effects on the metabolic landscape of cells. These include alterations to the metabolome, redox state, mitochondrial respiration, glucose utilization, and nitrogen metabolism and were either common to all cell lines tested or were cell line-specific. While the causes for many of the changes are unexplained, they do reveal the profound impact of media composition on cellular metabolism.
The Uric Acid Component of HPLM Has Striking Effects on De Novo Pyrimidine Biosynthesis
Among the most dramatic consequences of culture in HPLM +dIFS compared to that in RPMI, were increases in the intracellular abundances of four metabolites involved in nucleotide metabolism: carbamoylaspartate, dihydroorotate, orotate, and orotidine ( Figures 4A-4D ). As none of the four could be detected in either medium, the cause of these changes was not immediately apparent. The first three are intermediates in the de novo pyrimidine biosynthesis pathway that generates UMP, while orotidine is the dephosphorylation product of orotidine-5'-monophosphate (OMP), which is the immediate precursor to UMP in this pathway ( Figure 4E ). In four of the six cell lines examined, culture in HPLM +dIFS also reduced by 40%-60% the intracellular levels of the UTP and CTP pyrimidine nucleotides ( Figure 4F-4G ), but did not have similar effects on purine nucleotides ( Figure S4 ). Cell line-dependent contributions of salvage pathway activities (Evans and Guy, 2004) (red) or RPMI +IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
(D) Fraction of GPC labeled with three 13 C (M3) following culture of cells in HPLM +dIFS (red) or RPMI +IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
(E) Fraction of F6P/G1P labeled with six 13 C (M6) following culture of cells in HPLM +dIFS (red) or RPMI +IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
(F) Fraction of alanine labeled with three 13 C (M3) following culture of cells in HPLM +dIFS (red) or RPMI +IFS (gray) (mean ± SD, n = 3; **p < 0.0005).
(G) Schematic depicting the transaminase-mediate transfer of 15 N from the a-amino nitrogen of glutamine onto various amino acids. See Table S2 See also Figure S3 and Table S2. RPMI +dIFS , respectively ( Figure 5C ), and, importantly, its intracellular concentration reflects that of the corresponding culture medium ( Figure 5D ). In K562 cells, uric acid dose-dependently increased orotate and orotidine abundances ( Figure 5E ), and at its highest tested concentration (700 mM), led to a detectable accumulation of OMP. The addition of 350 mM uric acid to RPMI +IFS also greatly boosted orotate and orotidine levels, but, like complete HPLM, had cell line-dependent effects on UTP abundance ( Figure 5F ). Lastly, the closely related molecule 9-methyluric acid (9-MUA) entered K562 cells (Table S2 ), but did not alter the levels of orotate, orotidine, or the other intermediates in the de novo pyrimidine biosynthesis pathway ( Figure 5G ). The effects of uric acid on pyrimidine metabolism are particularly interesting because its plasma concentrations are up to an order of magnitude greater in humans, chimpanzees, gorillas, and additional higher primates than in other mammals (Á lvarezLario and Macarró n-Vicente, 2010; Kratzer et al., 2014; Wu et al., 1992) . Whereas most mammalian species, including mouse and cow, metabolize uric acid to allantoin via the liver enzyme uricase, the gene encoding uricase (UOX) became inactivated via pseudogenization during hominid evolution (Kratzer et al., 2014; Oda et al., 2002; Wu et al., 1992 Wu et al., , 1989 . As a consequence, uric acid, rather than allantoin, is the end product of purine catabolism in many higher primates ( Figure 5H ). Furthermore, in mice, which have a plasma uric acid concentration of $30 mM, uricase activity is essential, given that most UOX null mice die within 4 weeks of life from extreme hyperuricemia and nephropathy (Wu et al., 1994) . Thus, the finding that uric acid impacts the de novo pyrimidine biosynthesis pathway would have been difficult to make by studying cells growing in mice or cultured in conventional media.
Uric Acid Is a Direct Inhibitor of UMPS
In addition to boosting the intracellular levels of orotate and orotidine, HPLM also markedly increased their secretion into the media ( Figures S5A and S5B )-a phenomenon reminiscent of the high urinary excretion of these metabolites in patients with orotic aciduria and orotidinuria. As this disorder can be caused by the genetic ( (E) Relative intracellular abundances of orotate and orotidine following culture of K562 cells in HPLM +dIFS containing increasing concentrations of uric acid compared to that in standard HPLM +dIFS , which contains 350 mM uric acid (mean ± SD, n = 3).
(F) Relative intracellular abundances of orotate, orotidine (left) (mean ± SD, n = 3; p < 0.0005 for all bars), and UTP (mean ± SD, n = 3; *p < 0.005; **p < 0.0005) (right) following culture of cells in RPMI +IFS supplemented with 350 mM uric acid compared to that in RPMI +IFS .
(legend continued on next page)
1961; Suchi et al., 1997) or pharmacological (Bono et al., 1964; Fallon et al., 1961; Fox et al., 1970; Kelley and Beardmore, 1970) inhibition of UMP synthase (UMPS), we considered the possibility that the uric acid component of HPLM leads to the inhibition of this enzyme in cells. UMPS is a bifunctional twodomain enzyme that catalyzes the final two steps of the de novo pyrimidine biosynthesis pathway to generate UMP (Jones, 1980) . In the first step, the orotate phosphoribosyltransferase (OPRT) domain synthesizes OMP from orotate and PRPP, and in the second, the OMP decarboxylase (ODC) domain converts OMP to UMP ( Figure 6A ). To pursue the idea that uric acid might cause inhibition of UMPS, we first asked if an established UMPS inhibitor had similar effects on the de novo pyrimidine biosynthesis pathway as uric acid in our cells. The small molecules allopurinol and 6-azauridine are prodrugs that, upon conversion into allopurinol ribonucleotide and 6-aza-UMP (Bono et al., 1964; Handschumacher, 1960; Kelley and Beardmore, 1970; Murrell and Rapeport, 1986) , respectively, competitively inhibit the ODC domain of UMPS ( Figure 6B ). Indeed, in K562 cells, allopurinol dosedependently increased the levels of carbamoylaspartate, dihydroorotate, orotate, orotidine, and OMP (Figures S6A and S6B) . Moreover, at its highest tested concentration, allopurinol also decreased by nearly 30% the abundance of UTP in these cells ( Figure S6C ). Using LC/MS-based metabolite profiling, we detected a species whose mass-to-charge ratio (m/z) matched the predicted m/z of allopurinol ribonucleotide and whose magnitude correlated with the concentration of allopurinol in the media ( Figure S6D ). Importantly, this species could be distinguished from its isomer, IMP, by their differing chromatographic retention times. These data are consistent with the conversion of allopurinol to allopurinol ribonucleotide within the cell. However, despite substantial efforts, we failed to detect in cells a metabolite peak consistent with a putative uric acid ribonucleotide. Thus, we considered if uric acid itself might directly inhibit UMPS.
To investigate this possibility, we developed an in vitro UMPS activity assay containing recombinant UMPS ( Figure S6E ) and its substrates, orotate and PRPP, and verified its activity via the liquid chromatography-mass spectrometry (LC/MS) detection of OMP and UMP ( Figure 6C ). A UMPS mutant (Y37A, R155A), which was designed based on a recently deposited structure of the OPRT domain of human UMPS (Protein Data Bank entry 2WNS, chains A and B) ( Figure S6F ), had no activity and served as a negative control in the assay. As anticipated, the established ODC inhibitor, 6-aza-UMP, dose-dependently decreased UMP production by UMPS, and at 50 mM, reduced UMP levels to $3% of those in reactions containing vehicle ( Figure 6D ). 6-aza-UMP also dramatically increased the abundance of OMP, but the boost in OMP did not tightly correlate with the decrease in UMP, perhaps owing to the known reversibility of the OPRT reaction (Traut and Jones, 1977) .
Remarkably, uric acid also dose-dependently inhibited UMP production by UMPS and, like 6-aza-UMP, also increased OMP in a fashion that did not completely correlate with the decrease in UMP ( Figure 6E ). Uric acid was far less potent than 6-aza-UMP, as at 1 mM, it could only reduce UMP levels to $30% of those in reactions containing vehicle. Importantly, however, uric acid inhibited UMPS in vitro at concentrations consistent with those that boosted orotate and orotidine levels in cultured cells. Lastly, allopurinol and 6-azauridine did not directly inhibit UMPS and neither did 9-MUA or allantoin ( Figure 6F ).
Thus, we conclude that uric acid, at the concentrations present in human plasma, is a direct inhibitor of the ODC domain of UMPS.
Uric Acid Antagonizes the Cytotoxicity of 5-Fluorouracil 5-Fluorouracil (5-FU) is an antimetabolite drug that, although developed over 50 years ago, remains widely used in the treatment of several types of cancer (Longley et al., 2003) . In cells, 5-FU is metabolized into various fluoronucleotide derivatives that mediate its cytotoxic effects ( Figure 7A ). Among these is fluorouridine triphosphate (FUTP), which leads to cell death upon its misincorporation into RNA. FUTP synthesis begins with the conversion of 5-FU to fluorouridine monophosphate (FUMP), either directly by the OPRT domain of UMPS or indirectly through the sequential activities of uridine phosphorylase and uridine kinase (Longley et al., 2003) . Previous kinetic studies show that orotate competes with 5-FU for its direct conversion to FUMP by OPRT activity (Reyes and Guganig, 1975) (Figure 7B ). Consistent with these findings, allopurinol reduces the sensitivity of certain cancer cell lines to 5-FU (Schwartz and Handschumacher, 1979) , owing to orotate accumulation induced by competitive inhibition of the ODC domain of UMPS mediated by allopurinol ribonucleotide. Thus, we reasoned that uric acid might impact the sensitivity of cells to 5-FU through a similar mechanism.
Indeed, culture of NOMO1 cells in HPLM +dIFS increased the EC 50 of 5-FU by $5-and $8-fold compared to in RPMI +IFS and RPMI +dIFS , respectively ( Figure 7C ), without affecting the potency of doxorubicin-a DNA-damaging drug also commonly used in the treatment of cancer ( Figure 7D ). Moreover, removal of just uric acid from HPLM +dIFS reduced the EC 50 of 5-FU in NOMO1 cells by nearly 6-fold ( Figure 7E ), again without affecting doxorubicin sensitivity ( Figure 7F ). In cells treated with 5-FU and cultured in HPLM +dIFS lacking uric acid, we readily detected FUMP, fluorodeoxyuridine monophosphate (FdUMP), as well as 5-FU ( Figure 7G ). While culture in uric acid-containing HPLM +dIFS had little effect on the intracellular abundances of FdUMP and 5-FU, it reduced FUMP levels below the limit of (G) Relative intracellular abundances of carbamoylaspartate, dihydroorotate, orotate, and orotidine following culture of K562 cells in HPLM +dIFS containing either 350 mM uric acid (red) or 350 mM uric acid 9-methyluric acid (9-MUA) (white) compared to that in HPLM +dIFS lacking uric acid (mean ± SD, n = 3).
(H) Schematic depicting the pathways that influence the plasma concentrations of uric acid; 1: glomerular filtration (70%), 2: secretion (10%), 3: reabsorption (90%), 4: excretion (30%) (Bobulescu and Moe, 2012) . In contrast to most mammals, humans and many higher primates lack uricase (UOX) activity, which converts uric acid to allantoin (left). Concentrations of uric acid and allantoin in mouse plasma as measured by metabolite profiling in this study (n = 4). detection, consistent with the predicted antagonism of OPRTmediated FUMP synthesis by orotate ( Figure 7G ).
As 5-FU is no longer used in the treatment of hematological cancers, we also asked if uric acid affects the 5-FU sensitivity of a more clinically relevant cancer cell line (Longley et al., 2003) . As in the six hematological cancer cell lines, culture of the SW620 colorectal cancer cell line in HPLM +dIFS increased the intracellular abundance of orotate ( Figure S7A ), indicating that uric acid might also affect the 5-FU sensitivity of these cells. Indeed, removal of just uric acid from HPLM +dIFS reduced the 5-FU EC 50 of SW620 cells by 3-fold relative to that in HPLM +dIFS ( Figure S7B ), but did not influence doxorubicin sensitivity ( Figure S7C ). Thus, at concentrations found in human plasma, the endogenous metabolite uric acid affects the sensitivity of cancer cells to a common chemotherapeutic ( Figure 7H ). It is interesting to consider whether manipulations of plasma uric acid levels, such as by administration of uricase (Jeha et al., 2005) , could improve the 5-FU sensitivity of human tumors that generate FUMP via OPRT-mediated synthesis. (legend continued on next page)
Conclusions
Although the impact of environmental factors on cell metabolism is increasingly appreciated, traditional culture media and mouse plasma poorly reflect the metabolite composition of human plasma. Cell culture in a new medium, which better reflects the polar metabolite composition of human plasma (HPLM +dIFS ), had widespread effects on cellular metabolism compared to that in established media. Among the most dramatic were alterations in the intracellular abundance of metabolites involved in pyrimidine metabolism. We ultimately traced this effect to uric acid, whose plasma concentration is up to an order of magnitude greater in humans than in most other mammals, including mouse and cow (Á lvarez-Lario and Macarró n-Vicente, 2010; Kratzer et al., 2014; Wu et al., 1992) . We find that uric acid, at concentrations present in human plasma, is an endogenous inhibitor of UMPS, which catalyzes the final two steps of the de novo pyrimidine biosynthesis pathway. Similar to other small molecule inhibitors of UMPS, uric acid induces an accumulation of orotate, which in turn, antagonizes the metabolism of 5-FU to the fluoronucleotide derivatives that mediate its cytotoxic effects. Through the use of HPLM, we uncovered a role for an endogenous metabolite that would have been difficult to discover by studying cells cultured in established media or in mouse models (Wu et al., 1994) . Although the causes of the many other changes to the metabolic landscape induced by HPLM are unexplained, they do reveal the impact of media composition on cellular metabolism and suggest the potential to generate HPLM derivatives that reflect plasma metabolite conditions associated with particular pathophysiological states or lifestyles. Moreover, in the future it will be interesting to generate HPLM derivatives with additional components, such as proteins and lipids, at concentrations resembling those of adult human plasma and to consider how HPLM affects other biological processes, including cellular differentiation. We conclude that HPLM should be of broad utility to study cellular metabolism and may help reveal new tumorspecific liabilities or metabolite-drug interactions that are influenced by environmental metabolic composition.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Collection of Mouse Plasma
The MIT Institutional Animal Care and Use Committee approved procedures used for the collection of whole blood. Male C57BL/6J mice, 3.5 months old, were maintained on regular chow at the specific pathogen free animal facility of the Whitehead Institute, and were fasted for 18 hr prior to blood collection. At 10:00 AM, 100 mL of blood was collected into heparinized tubes (Sarstedt Microvette 200 LH) from the facial vein, and the plasma fraction was collected following centrifugation at 850 g for 6 min at 4 C.
Collection of Human Plasma
At 6:00 AM, 10 mL of blood from the corresponding author (male, 48 years old) was collected into a heparinized tube (BD Vacutainer 366480) from the antecubital vein for blood glucose testing. Upon transferring 100 mL from the remaining blood to a fresh heparinized tube (Sarstedt Microvette 200 LH), the plasma fraction was collected following centrifugation at 850 g for 6 min at 4 C.
Primary Cell Isolation
A primary human acute myeloid leukemia specimen (estimated blast percentage of 80%; CD33+ CD13+ MPO-, CD117+, CD34+, HLA-DR+, CD71dim+) was collected from the bone marrow of a patient (male, 73 years old) at the Massachusetts General Hospital (MGH) as approved by the MGH Institutional Review Board. To remove red blood cells (RBCs), the specimen was added to a 20X volume of RBC lysis buffer (BioLegend 420301) and mixed well at room temperature. After 15 min incubation, cells were centrifuged at 650 g for 5 min at room temperature, resuspended in 5 mL PBS, again centrifuged using the same settings, and finally, resuspended in 2.5 mL PBS.
Cell Lines
The following cell lines were kindly provided by: K562 and NOMO1, Dr. James Griffin ( , and SW620) were purchased from ATCC. Cell lines were verified to be free of mycoplasma contamination (Freshney, 2010) and the identities of all cell lines other than CLF-PED-015T (received at passage 7) and BJ (received at passage 1) were authenticated by STR profiling. We note the STR profile for SW620 cells revealed very minor background at 2 of the 10 loci evaluated, perhaps as a consequence of genetic drift over the course of passaging.
Cell Culture Conditions
Cells were primarily cultured in the following media:
(1) RPMI +IFS : RPMI 1640 lacking glucose (Thermo Fisher Scientific 11879020) to which we added 5 mM glucose, 10% heat inactivated fetal bovine serum (IFS), penicillin, and streptomycin. Table S1 ) to which we added 10% dialyzed IFS, RPMI 1640 100X Vitamins (Sigma-Aldrich R7256), penicillin, and streptomycin.
Using SnakeSkin dialysis tubing, 3.5K MWCO, 35 mm (Thermo Fisher Scientific PI88244), IFS was dialyzed against a 20X volume of PBS. Dialysis was carried out for 48 hr at 4 C with a complete PBS exchange every 9-12 hr. Prior to use, all media were sterile filtered using bottle-top vacuum filters, cellulose acetate membrane, pore size 0.45 mm (Sigma-Aldrich CLS430514).
Prior to experiments, cells were grown in the medium of interest for at least two passages unless otherwise noted. Cells were typically split in the range 1:3 to 1:5 into fresh medium. All cells were maintained at 37 C and 5% CO 2 . For the short-term culture of primary AML cells, media were supplemented with 50 mM b-mercaptoethanol (Thermo Fisher Scientific 21985023), 100 ng/mL human SCF (Peprotech 300-07), 10 ng/mL human IL-3 (Peprotech 200-03), 20 ng/mL human IL-6 (Peprotech 200-06), 10 ng/mL human TPO (Peprotech 300-18), and 10 ng/mL FLT3L (Peprotech 300-19).
For HEK293T transfection experiments, cells were cultured in DMEM supplemented with 10% IFS, penicillin, and streptomycin.
METHOD DETAILS Plasmid Construction
All plasmids and primers used in this study are described in Table S4 . All plasmids generated in this study are deposited in Addgene. Construction of lentiviral plasmid pLJC2-Rap2A-3xFLAG
The KRASV12 gene was amplified from the pDONR223-KRASV12 template using the primers JC4/JC5, digested with AgeI-BamHI, and cloned into pLJM1-eGFP to generate pLJM1-KRASV12-3xFLAG. Plasmid pLJC1-KRASV12-3xFLAG was constructed using QuickChange PCR to remove two NotI sites of pLJM1-KRASV12-3xFLAG with the primers JC48/JC49 and JC50/JC51, respectively. The Rap2A gene was amplified from the pLJM1-Rap2A template using the primers JC68/JC69, digested with PacI-NotI, and cloned into pLJC1-KRASV12-3xFLAG to generate pLJC1-Rap2A-3xFLAG. The sequence encoding Rap2A-3xFLAG was then amplified from pLJC1-Rap2A-3xFLAG using the primers JC_LJC2-F/JC79, digested with AgeI-EcoRI, and cloned into pLJM1-eGFP to generate pLJM1-Rap2A-3xFLAG. Plasmid pLJC2-Rap2A-3xFLAG was then constructed using QuickChange PCR to remove two NotI sites of pLJM1-Rap2A-3xFLAG with the primers JC48/JC49 and JC50/JC51, respectively.
Construction of UMPS plasmids
The UMPS gene was amplified from the pDONR223-UMPS template using the primers JC624/JC625, digested with PacI-NotI, and cloned into pLJC2-Rap2A-3xFLAG to generate pLJC2-UMPS-3xFLAG. Plasmid pLJC2-UMPS (Y37A, R155A)-3xFLAG was constructed using a 2-step protocol based on overlap extension PCR methodology. In the first step, three fragments were amplified from the pLJC2-UMPS-3xFLAG template using the following primer pairs: JC_LJC2-F/JC716, JC715/JC720, and JC719/JC_LJC2-R. In the second step, the three fragments were pooled in a second PCR containing the primers JC_LJC2-F/JC_LJC2-R, then digested with PacI-NotI, and cloned into pLJC2-UMPS-3xFLAG.
Design of HPLM
The Human Metabolome Database, which is integrated with the Serum Metabolome Database, (Psychogios et al., 2011; Wishart et al., 2013) contains 2,192 metabolites that were designated as being both detected and quantified in at least one human biofluid. From this collection, we removed molecules that met one of the following manually applied filtering criteria: (1) Metabolites for which a concentration in normal adult human blood was not indicated; (2) Lipophilic metabolites, including fatty acids, cholesterol, and derivatives of the following: cholesterol ester, ceramide, diglyceride, ganglioside, glycerophosphocholine, monoacylglyceride, phosphatidic acid, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, sphingomyelin, and triglyceride; (3) Metabolites with concentrations in normal adult human blood < 6 mM as denoted by at least one reference source; (4) Metabolites with concentrations in normal adult human blood indicated by only one reference source; and (5) Metabolites that were not commercially available. Although vitamins are among the nutritional requirements of cells in culture (Eagle, 1955c) , most had annotated plasma concentrations that were well below the 6 mM threshold we set. Therefore, rather than omit these metabolites, we chose to supplement HPLM with a commercial concentrated mixture of vitamins at concentrations equivalent to those of RPMI 1640. In addition, while trace elements such as copper and zinc are also essential for cells in culture, they are often contributed in sufficient quantities by transport molecules in IFS, such as albumin and insulin, and exceeding their necessary levels is often detrimental to cell proliferation (SigmaAldrich Media Expert; Online Resource). Thus, we did not include trace elements among the defined components of HPLM.
Additional modifications, such as removal of non-endogenous compounds and gases, were also made to generate the final list of 20 proteinogenic amino acids, 27 additional polar metabolites, and 10 small ions included in the formulation of HPLM at concentrations similar to the calculated average of values reported for normal adult human blood. As anticipated, the metabolite concentrations of plasma collected from the corresponding author (See Collection of Human Plasma; Polar metabolite profiling and quantification of metabolite abundance) largely reflected those of HPLM. See Table S1 .
Growth Curves
For suspension cells, all cell lines were seeded at a density of 100,000 cells/mL in 12 mL culture medium and grown in 25 cm 2 rectangular canted neck cell culture flasks (Westnet 430639). Cell density measurements were recorded every 9-12 hr using a Beckman Z2 Coulter Counter with a diameter setting of 8-30 mm. For each adherent cell line, 100,000 total cells were seeded in 3 mL culture medium in each of nine technical replicates, and grown in 6-well plates. Every 9-12 hr, one replicate was aspirated, washed in 1 mL PBS, trypsinized, and used to analogously obtain cell density measurements. Points for time versus natural log-transformed cell density were plotted in GraphPad Prism and those comprising the exponential growth phase were fit using a linear regression equation. Specific growth rates were equivalent to slopes of the fit lines.
Polar Metabolite Profiling and Quantification of Metabolite Abundance LC/MS-based analyses were performed on a QExactive benchtop orbitrap mass spectrometer equipped with an Ion Max source and HESI II probe, which was coupled to a Dionex UltiMate 3000 UPLC system (Thermo Fisher Scientific). External mass calibration was performed using the standard calibration mixture every 7 days. Acetonitrile was LC/MS HyperGrade (EMD Millipore). All other solvents were LC/MS Optima grade (Thermo Fisher Scientific).
Media and Plasma
For metabolite profiling of media and plasma, samples were diluted 1:40 in a solution containing 50% methanol, 30% acetonitrile, 20% water and either phenylalanine-d 8 (Cambridge Isotope Laboratories DLM-1372) at 10 ng/mL or a mixture of 17 isotope-labeled amino acids (Cambridge Isotope Laboratories MSK-A2-1.2) each at 909 nM as internal standard(s) (Metabolite Composition of Cultured Media samples) and then stored at À80 C. Following a 5 min vortex and centrifugation at 21130 g for 5 min at 4 C, 2 mL of each sample was injected onto a ZIC-pHILIC 2.1 3 150 mm analytical column equipped with a 2.1 3 20 mm guard column (both 5 mm particle size, EMD Millipore). Buffer A was 20 mM ammonium carbonate, 0.1% ammonium hydroxide; buffer B was acetonitrile. The chromatographic gradient was run at a flow rate of 0.150 mL/min as follows: 0-20 min: linear gradient from 80% to 20% B; 20-20.5 min: linear gradient from 20% to 80% B; 20.5-28min: hold at 80% B. The mass spectrometer was operated in full scan, polarity-switching mode with the spray voltage set to 3.0 kV, the heated capillary held at 275 C, and the HESI probe held at 350 C. The sheath gas flow rate was set to 40 units, the auxiliary gas flow was set to 15 units, and the sweep gas flow was set to 1 unit. The MS data acquisition was performed in a range of 70-1000 m/z, with the resolution set to 70,000, the AGC target at 10 6 , and the maximum integration time at 20 msec.
Suspension Cell Lines
For metabolite profiling whole-cell suspension samples, cells were pelleted and then seeded at a density of 200,000 cells/mL in 6-well plates in 3 mL of fresh culture medium. After 24 hr incubation, cells were centrifuged at 250 g for 5 min, resuspended in 1 mL ice-cold 0.9% sterile NaCl (Bioexpress MSDW-1000), and again centrifuged at 250 g for 5 min at 4 C. Metabolites were extracted in a 1 mL solution of 80% methanol containing 10 ng/mL phenylalanine-d 8 as an internal standard. Following a 10 min vortex and centrifugation for 3 min at 21130 g for 10 min at 4 C, samples were dried under nitrogen gas. Dried samples were stored at À80 C and then resuspended in 100 mL water. Following a 10 min vortex and centrifugation at 21130 g for 10 min at 4 C, 4 mL of each cell sample was injected for LC/MS analysis as described above for profiling media samples. For all experiments, an additional culture replicate was set up identically and used for measuring cell number and volume, which were each measured using a Beckman Z2 Coulter Counter with a diameter setting of 8-30 mm. Adherent Cell Lines For metabolite profiling whole-cell adherent samples, cells were pelleted and then seeded at one of the following densities in 6-well plates in 3 mL of fresh culture medium: 70,000 cells/mL (786-0); 100,000 cells/mL (A549); 70,000 cells/mL (MCF7); 200,000 cells/mL (SW620); 80,000 cells/mL (BJ); and 100,000 cells/mL (CLF-PED-015T). After 24 hr incubation, wells were aspirated on ice, briefly washed in 1 mL ice-cold 0.9% sterile NaCl, and then extracted in a 1 mL solution of 80% methanol containing 10 ng/mL phenylalanine-d 8 as an internal standard. Subsequent steps were identical to those described above for profiling suspension cell samples. For CLF-PED-015T, cells were grown in the medium of interest for two passages prior to profiling to minimize the passage number at which they were profiled. Primary AML Cells Following RBC removal from the primary leukemia specimen (See Primary Cell Isolation), a 1 mL aliquot of isolated cells was centrifuged at 21130 g for 15 s, resuspended in 10 mL of culture medium (RPMI +IFS or HPLM +dIFS ) supplemented with human cytokines (See Cell Culture Conditions), and seeded equivalently across four wells of a 6-well plate. After 8 hr incubation, cells were pooled, centrifuged at 21130 g for 15 s, and resuspended in 1 mL ice-cold 0.9% NaCl. From this resuspension, 100 mL was used to obtain the number and volume of viable cells in each sample using a Beckman Z2 Coulter Counter with a diameter setting of 5-24 mm. The remainder of cells were centrifuged at 21130 g for 15 s, and then extracted in a 1 mL solution of 80% methanol containing 10 ng/mL phenylalanine-d 8 as an internal standard. Subsequent steps were identical to those described above for profiling suspension cell samples.
NAD/NADH
For metabolite profiling whole-cell suspension samples to specifically quantify NAD and NADH, cells were pelleted and then seeded at a density of 200,000 cells/mL in 6-well plates in 3 mL of fresh culture medium. After 24 hr incubation, cells were centrifuged at 250 g for 5 min, resuspended in 1 mL ice-cold 0.9% sterile NaCl, and again centrifuged at 250 g for 5 min at 4 C. Metabolites were extracted in a 500 mL solution of 80% methanol containing 10 ng/mL phenylalanine-d 8 as an internal standard. Following a 10 min vortex and centrifugation for 3 min at 21130 g for 10 min at 4 C, samples were immediately injected for LC/MS analysis as described for wholecell samples otherwise. Metabolite Profiling of UMPS Activity Assay For metabolite profiling of UMPS activity assay samples, reaction mixtures were extracted (See UMPS Activity Assay) and 5 mL of each sample was injected for LC/MS analysis as described otherwise, except that the mass spectrometer was operated in full scan, negative ionization mode only. 5-FU Treatment NOMO1 cells were pelleted and then seeded at a density of 200,000 cells/mL in 6-well plates in 3 mL of culture medium containing 20 mM 5-FU. After 24 hr incubation, metabolite extractions were performed identically to those described above for profiling suspension cell samples. Quantification A list of nearly 170 metabolites encompassing a variety of metabolic pathways and processes was created with the intention of exploring the metabolome in a global and targeted fashion. From a library of chemical standards assembled by the Whitehead Institute Metabolite Profiling core facility, we constructed six pools of standards (See Table S1 for the composition of each pool) that together accounted for nearly 90% of this list. Standards were validated by LC/MS to confirm that they generated robust peaks at the expected m/z ratio. Stock solutions of each pool, containing 1 mM of each metabolite in water, were stored at À80 C. On the day of each run, these stocks were serially diluted in water, further diluted 1:10 into appropriate extraction solution, and then run in parallel with a given batch of biological samples.
Metabolite identification and quantification were performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) using a 10 ppm mass accuracy window and 0.5 min retention time window. To confirm metabolite identities and to enable quantification, the aforementioned pools of metabolite chemical standards were used. Typically, the final concentrations of standards were 10 nM, 100 nM, 1 mM, 10 mM, and 100 mM. For glucose, chemical standard solutions were also made at concentrations of 125 mM and 250 mM. For NAD and NADH, standards at 10 nM were omitted. For certain metabolites, chemical standards were utilized only for metabolite identification. For those metabolites lacking a chemical standard, peak identification was restricted to high confidence peak assignments (Smith et al., 2005) . See Table S1 .
Because metabolite extraction protocols differed by sample type, the concentration of phenylalanine-d 8 in processed samples varied: chemical standard pools (9 ng/mL), media and plasma samples (9.75 ng/mL), and cell samples (100 ng/mL). Therefore, the raw peak area of phenylalanine-d 8 within each sample of a given batch was first normalized to account for these differences. To quantitate metabolites, we first divided the raw peak area of each metabolite by its corresponding normalized phenylalanine-d 8 peak area. From the normalized metabolite peak areas of a given chemical standard, we then generated a corresponding standard curve fit to a quadratic log-log equation, typically with r 2 > 0.95, which was used to determine the metabolite concentration in each biological metabolite extract. The total number of moles of a metabolite in a particular whole-cell or medium/plasma extract was then calculated from the sample concentration and the corresponding sample volume. Thus, final metabolite concentrations in biological samples were calculated using the appropriate equation below:
Media and plasma samples : Concentration by standard curve 3 40
Wholecell samples : Concentration by standard curve 3 100=ðcell volume; in mLÞ Wholecell NAD=NADH samples : Concentration by standard curve 3 500=ðcell volume; in mLÞ
For those metabolites that were not quantified using a standard curve, normalized peak areas were used in the above calculations. For whole-cell profiles of adherent cell lines and primary AML cells, normalized peak areas were used for all metabolites.
Highly Targeted Metabolomics For the highly targeted analyses of FdUMP and FUMP in whole-cell samples following 5-FU treatment, the instrument was run as described (See Media and Plasma), but with an additional tSIM (targeted selected ion monitoring) scan in negative ionization mode. The tSIM settings were as follows: resolution set to 70,000, an AGC target of 10 5 , and a maximum integration time of 250 msec. The target masses were 325.0243 (corresponding to FdUMP) and 341.0192 (corresponding to FUMP). The isolation window around each target mass was set to 1.0 m/z. For orotate, PRPP, OMP, and UMP in UMPS assay samples, all settings as described for the tSIM scan used for FdUMP and FUMP were identical except that the maximum integration time was 200 msec, and the target masses were 155.0098 (corresponding to orotate), 323.0286 (corresponding to UMP), 367.0184 (corresponding to OMP), and 388.9445 (corresponding to PRPP).
For NAD and NADH in whole-cell samples, all settings as described for the tSIM scan used for FdUMP and FUMP were identical except that the target masses were 662.1019 (corresponding to NAD) and 664.1175 (corresponding to NADH).
For carbamoylaspartate, orotate, and orotidine in primary AML whole-cell samples, all settings as described for the tSIM scan used for FdUMP and FUMP were identical except that the target masses were 175.036 (corresponding to carbamoylaspartate), 155.0098 (corresponding to orotate), and 287.0521 (corresponding to orotidine).
For pyruvate and succinate in media samples profiled following 24 hr cell culture, all settings as described for the tSIM scan used for FdUMP and FUMP were identical except that the target masses were 87.0088 (corresponding to pyruvate) and 117.0193 (corresponding to succinate).
Labeling Experiments
Cells were pelleted and then seeded at a density of 200,000 cells/mL in 6-well plates in 3 mL of culture medium containing either 5 mM [U-13 C]-glucose or 550 mM [a- 15 N]-glutamine. After 24 hr incubation, metabolite extractions were performed identically to those described for profiling suspension cell samples (See Polar metabolite profiling and quantification of metabolite abundance). For [a-15 N]-glutamine tracing studies, the RPMI media were prepared using SILAC RPMI 1640 Flex Media (Thermo Fisher Scientific A2494201), to which we added 5 mM glucose, 14 mM phenol red, 1.15 mM arginine, 270 mM lysine, penicillin, streptomycin, and [a- 15 N]-glutamine at the concentration noted above.
Lipidomics of Culture Media LC/MS-based analyses were performed using the same QExactive benchtop orbitrap mass spectrometer and Dionex UltiMate 3000 UPLC system described otherwise (See Polar metabolite profiling and quantification of metabolite abundance). For lipid profiling of media, 95 mL methanol and 190 mL dichloromethane were sequentially mixed by 20 s vortex with 15 mL of medium. Following addition of 60 mL water to the mixture, samples were vortexed for 10 min at 4 C, and then centrifuged at 8000 g for 10 min at 4 C. From the resulting two-phase solution, 100 mL of the bottom (lipid) fraction was carefully collected and dried under nitrogen gas. Dried samples were stored at À80 C and then resuspended in a 50 mL solution of 65% acetonitrile, 30% isopropanol, and 5% water. Following a 10 min vortex and centrifugation at 21130 g for 5 min at 4 C, 5 mL was injected onto an Ascentis Express C18 2.1 3 150 mm 2.7 mm column (Sigma-Aldrich).
Buffer A was a solution of 60% water, 40% acetonitrile, 10 mM ammonium formate (Sigma-Aldrich), and 0.1% formic acid (Pierce); buffer B was a solution of 90% isopropanol, 10% acetonitrile, 10 mM ammonium formate, and 0.1% formic acid. The chromatographic gradient was run at a flow rate of 0.260 mL/min as described previously (Hu et al., 2008) : 0-1.5 min, isocratic elution with 32% B; from 1.5 to 4 min, increase to 45% B; from 4 to 5 min, to 52% B; from 5 to 8 min, to 58% B; from 8 to 11 min, to 66% B; from 11 to 14 min, to 70% B; from 14 to 18 min, to 75% B; from 18 to 21 min, to 97% B; from 21 to 25 min, maintain at 97% B; from 25 to 25.1 min, decrease to 32% B and maintain for an additional 4.9 min for column re-equilibration. The column oven and autosampler tray were held at 55 C and 4 C, respectively. Separate injections for positive and negative ionization modes were made for each sample. The spray voltage was set to 4.2 kV and the heated capillary and HESI were held at 320 C and 300 C, respectively. The S-lens RF level was set to 50, and the sheath and auxiliary gas were set to 35 and 3 units, respectively. These conditions were held constant for both positive and negative ionization mode acquisitions. The MS data acquisition was performed in a full scan/data-dependent MS 2 mode. For the full scan acquisition, the resolution was set to 70,000, the AGC target at 10 6 , the maximum integration time at 50 msec, and the scan range was 133.4-2000 m/z.
High-throughput identification and relative quantification of lipids was performed separately for positive and negative ionization mode data using LipidSearch software (Thermo Fisher Scientific) (Taguchi and Ishikawa, 2010; Yamada et al., 2013) using the default parameters for QExactive Product Search and Alignment. After alignment, raw peak areas for all identified lipids were exported to Microsoft Excel and filtered according to the following pre-determined quality control criteria: Rej (''Reject'' parameter calculated by LipidSearch software) equal to 0; PQ (''Peak Quality'' parameter calculated by LipidSearch software) greater than 0.85; CV (standard deviation divided by the average peak area across triplicate injections of a representative pooled biological sample) below 0.4; R (linear correlation across a three-point dilution series of the representative pooled sample) greater than 0.9. Raw peak areas of the filtered lipids were added to generate a ''total lipid signal'' for each sample, and individual lipid peak areas were normalized to this total signal as a control for extraction efficiency and sample loading. Normalized peak areas for all filtered lipids designated within a particular lipid class were then summed to represent the total signal of that class in the sample. Finally, for free fatty acids, peak areas were obtained using XCalibur QuanBrowser 2.2 (See Polar metabolite profiling and quantification of metabolite abundance) and normalized using the ''total lipid signal'' for the corresponding sample as well. See Table S1 .
Cholesterol Quantification
Concentrations of total, LDL, and HDL cholesterol in IFS and dIFS were measured via enzymatic methods by the Yale Mouse Metabolic Phenotyping Center Analytical Core using a Cobas Mira Plus Analyzer (Roche Diagnostics). For total cholesterol, 3 mL of sample was added to 275 mL Cholesterol Rapid Liquid Reagent (Cliniqa R85464) and incubated at 37 C for 10 min prior to measurement of the absorbance at 500nm. For HDL cholesterol, 3 mL of sample was added to 180 mL HDL Cholesterol Direct Reagent 1 (Cliniqa R85549) and 60 mL HDL Cholesterol Direct Reagent 2 (Cliniqa R85549) and incubated at 37 C for 10 min prior to measurement of the absorbance at 600nm. For LDL cholesterol, 3 mL of sample was added to 225 mL LDL Direct Reagent 1 (Cliniqa R85556) and 75 mL LDL Direct Reagent 2 (Cliniqa R85556) and incubated at 37 C for 10 min prior to measurement of the absorbance at 600nm. For quantification purposes, the Cobas analyzer was calibrated using two chemical controls.
Net Exchange Rates
At each time point that cell density was measured during the construction of a particular growth curve, a small aliquot of the culture was carefully removed, centrifuged at 250 g for 5 min at 4 C, and metabolites were extracted from the supernatant as described for media and plasma samples, and then stored at À80 C (See Polar Metabolite Profiling and Metabolite Quantification). For a given growth curve, we profiled an extraction sample associated with a time point that fell in mid-exponential phase. We also profiled fresh media in parallel and the specific exchange rate for a given metabolite was obtained according to the simplified Monod model, q = m/Y X/S , which expands to: q = m 3 V 3 (DM/DX), where m is the specific growth rate, V is the culture volume, DM is the difference in metabolite concentration between the two time points, and DX is the difference in cell density between the two time points.
Metabolite Composition of Cultured Media
Cells were pelleted and then seeded at a density of 200,000 cells/mL in 6-well plates in 3 mL of fresh culture medium. After 24 hr incubation, a 100 mL aliquot of the culture was collected and centrifuged at 250 g for 5 min. Metabolites were then extracted from the supernatant as described for media and plasma samples, and then stored at À80 C (See Polar Metabolite Profiling and Metabolite Quantification).
Expression and Immunopurification of Recombinant UMPS
For transfection of HEK293T cells, 4 million cells were plated in 15 cm culture dishes. After 24 hr, cells were transfected with 15 mg of pLJC2-UMPS-3xFLAG or pLJC2-UMPS (Y37A, R155A)-3xFLAG using the polyethylenimine method (Boussif et al., 1995) . After 48 hr, cells were rinsed once with ice-cold PBS and then immediately lysed with lysis buffer (1% Triton X-100, 40 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM MgCl 2 , 1 tablet of EDTA-free protease inhibitor (Roche 11580800; per 25 mL buffer), 1 tablet of PhosStop phosphatase inhibitor (Roche 04906845001; per 10 mL buffer)). The cell lysates were cleared by centrifugation at 21130 g for 10 min at 4 C. For anti-FLAG immunoprecipitation, the FLAG-M2 affinity gel (Sigma A2220) was washed 3 times in lysis buffer. For each experiment, 500 mL of a 50/50 slurry of the affinity gel was then added to a pool of clarified lysates collected from 5 individual 15 cm culture dishes, and incubated with rotation for 3 hr at 4 C. Following immunoprecipitation, the beads were washed 2 times in lysis buffer and 3 times with lysis buffer containing 500 mM NaCl. Recombinant protein was then eluted in lysis buffer containing 1 mg/mL FLAG peptide for 1 hr at 4 C. The eluent was isolated by centrifugation at 100 g for 4 min at 4 C (BioRad micro bio-spin column 732-6204), buffer exchanged (Amicon Ultra 30K NMWL) against 20 volumes of storage buffer (40 mM Tris-HCl pH 7.5, 100 mM NaCl, 1.5 mM dTT), mixed with glycerol (final concentration 15% v/v), and finally snap-frozen with liquid nitrogen and stored at À80 C. Protein samples were quantified using Bradford reagent (Bio-Rad) and a BSA standard, and verified by 12% SDS-PAGE.
UMPS Activity Assay
Reactions of each purified UMPS variant (20-40 nM enzyme) with orotate (100 mM) and PRPP (300 mM) were carried out at 37 C in 20 mM Tris-HCl pH 7.5, 5 mM Na 2 HPO 4 , 5 mM MgCl 2 , 2 mM dTT, 100 mM EDTA (adapted from Han et al., 1995), and various concentrations of putative inhibitors in a total volume of 100 mL. Following 20 min incubation, a 15 mL aliquot of the reaction mixture was removed and immediately added to 85 mL ice-cold 80% methanol for metabolite extraction, vortexed for 5 min, and centrifuged at 21130 g for 1 min at 4 C. Stock solutions of 6-azauridine (Sigma-Aldrich A1882), 6-aza-UMP (Santa Cruz sc-291171), 9-methyluric acid (Santa Cruz sc-362184), allantoin (Sigma-Aldrich 05670), allopurinol (Sigma-Aldrich PHR1377), and uric acid (Sigma-Aldrich U2625) were made up fresh at 200 mM in 1 M NaOH, and upon appropriate dilutions, had little effect on reaction pH.
Using the peak areas of a UMP chemical standard (final concentrations 625 nM, 1.25 mM, 2.5 mM, 5 mM, and 10 mM) identically prepared in 80% methanol, we generated a standard curve fit to a linear equation to ensure that UMP concentrations in the reaction samples did not exceed 10% of the initial orotate concentration. An OMP chemical standard was not available.
Drug Treatments NOMO1 cells were seeded at a density of 16,667 cells/mL in 6-well plates in 3 mL of culture medium. After 24 hr incubation, cells were treated with 5-FU (Sigma-Aldrich F6627) (100 nM, 1 mM, 10 mM, 100 mM, or 1 mM) or doxorubicin (Sigma-Aldrich 44583) (1.95 nM, 7.81 nM, 31.25 nM, 125 nM, or 500 nM). All wells, including untreated controls, contained 0.5% DMSO. Following addition of drugs, plates were gently shaken for 2 min. After 4 days of treatment, 200 mL from each well was transferred to a white 96-well plate (Greiner) and cell viability was assessed with Cell Titer-Glo (Promega). Luminescence was measured with a SpectraMax M5 Plate Reader (Molecular Devices) and normalized to an untreated control. SW620 cells were seeded in white 96-well plates (Greiner) at a density of 2000 cells/well and allowed to attach for 24 hr. 5-FU and doxorubicin were prepared in DMSO and dispensed using an HP D300 compound dispenser. Cell viability was assessed with CellTiter Glo at 4 days following treatment and luminescence was measured as described above.
Dose-response values were plotted in GraphPad Prism and fit using a One Site-Fit logIC 50 equation.
Cell Lysis and Immunoblotting
To evaluate mTORC1 signaling, cells cultured in a given medium were pelleted and then seeded in each of three wells of a 6-well plate at a density of 333,000/mL in 3 mL of corresponding fresh culture medium. After 2 hr incubation, cells were pooled, centrifuged at 250 g for 5 min, resuspended in 1 mL ice-cold PBS, and again centrifuged at 250 g for 5 min at 4 C. Cells were then immediately lysed with lysis buffer (1% Triton X-100, 10 mM b-glycerol phosphate, 10 mM pyrophosphate, 40 mM HEPES pH 7.4, 2.5 mM MgCl 2 , and 1 table of EDTA-free protease inhibitor). The cell lysates were cleared by centrifugation at 21130 g for 10 min at 4 C and then quantified for protein concentration using Bradford reagent. Protein samples were normalized for protein content, denatured by the addition of Laemmli buffer, boiled for 5 min, resolved by 8% SDS-PAGE, and transferred to a polyvinyl difluoride membrane (Millipore).
Membranes were blocked with 5% nonfat dry milk prepared in TBST for 1 hr at room temperature, then incubated with primary antibodies in 5% BSA overnight at 4 C. Primary antibodies to the following proteins were used at the indicated dilutions: Raptor (EMD Millipore 09-217; 1:1000); S6 kinase (Cell Signaling Technology 2708; 1:5000); and Phospho-S6 kinase (Thr389) (Cell Signaling Technology 9234; 1:1000). Membranes were washed with TBST three times for 5 min each, and then incubated with secondary antibody (Goat anti-Rabbit IgG HRP, Santa Cruz sc-2054; 1:5000) in 5% nonfat dry milk for 1 hr at room temperature. Membranes were washed again with TBST three times for 5 min each, and then visualized using chemiluminescence (Thermo Fisher Scientific).
Virus Production and Transduction Efficiency
For transfection of HEK293T cells, pLJM1-eGFP was co-transfected with the VSV-G envelope plasmid and the Delta-VPR lentiviral packaging plasmid using XTremeGene 9 Transfection Reagent (Roche). Culture medium was exchanged 16 hr after transfection with the same medium instead supplemented with 20% IFS. The virus-containing supernatant was collected 48 hr after transfection and passed through a 0.45 mm filter to eliminate cells.
K562 cells were infected with eGFP lentivirus in culture medium containing 8 mg/mL polybrene (EMD Millipore) by centrifugation at 1200 g for 45 min at 37 C. After 24 hr incubation, cells were pelleted to remove virus and re-seeded into fresh culture medium. The efficiencies of transduction were evaluated 96 hr after infection by FACS (BD LSR Flow Cytometer) with gates applied to live cells that were GFP-positive.
Seahorse analysis
Oxygen consumption of intact cells was measured using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience). XF24 Cell Culture Microplates (Seahorse Bioscience) were coated with a solution containing 0.08 mg/mL Cell-Tak (Corning), 90 mM NaHCO 3 , and 33 mM NaOH to increase suspension cell adherence. After 20 min, all wells were washed twice with sterile water, and then seeded with either 200,000 (P12-Ichikawa, NOMO1, SEM) or 125,000 (SUDHL4) total cells in a volume of 500 mL. Cells were attached by centrifugation at 600 g for 10 min with no brake, transferred to an incubator lacking CO 2 for 30 min, and then transferred to a standard incubator. After 16 hr, basal oxygen consumption rates were determined on the XF24 Analyzer and normalized by cell number as measured following the assay using a Beckman Z2 Coulter Counter with a diameter setting of 8-30 mm.
QUANTIFICATION AND STATISTICAL ANALYSIS
All p values were calculated using a two-tailed unpaired t test in GraphPad Prism 6. All CV and R values calculated for filtering lipids identified in LipidSearch were determined in Microsoft Excel. All specific growth rates and r values describing the relationship between rates of glucose consumption and lactate secretion were derived from linear regression analyses performed in GraphPad Prism 6. The exact value of n and the definition of center and precision measures are provided in all figure legends. All instances where n replicates are reported had n biological replicates, except the metabolite profiling data described for primary AML, for which n instead denotes technical replicates.
DATA AND SOFTWARE AVAILABILITY Data Resources
Datasets can be found in Tables S1, S2 , and S3.
